CASI Pharmaceuticals (CASIF) Gross Profit (2022 - 2025)

CASI Pharmaceuticals has reported Gross Profit for 4 years, with the latest figure at $3.7 million in Q4 2025.

• For the quarter ending Q4 2025, Gross Profit rose 14.41% year-over-year to $3.7 million; the trailing twelve-month figure through Dec 2025 stood at $10.1 million (down 9.6% YoY), and the FY2025 full-year result was $10.1 million, down 9.6% from the prior year.
• Gross Profit for Q4 2025 stood at $3.7 million, up from $706000.0 in the prior quarter.
• The five-year high for Gross Profit was $11.0 million in Q4 2022, with the low at $706000.0 in Q3 2025.
• Historically, Gross Profit has averaged $4.3 million across 4 years, with a median of $4.1 million in 2023.
• The largest YoY upside for Gross Profit was 100.39% in 2025 against a maximum downside of 82.55% in 2025.
• CASI Pharmaceuticals' Gross Profit stood at $11.0 million in 2022, then tumbled by 63.06% to $4.1 million in 2023, then slipped by 20.47% to $3.2 million in 2024, then rose by 14.41% to $3.7 million in 2025.
• The last three Gross Profit figures came in at $3.7 million (Q4 2025), $706000.0 (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.